Condition: Craniopharyngioma, Child · Craniopharyngioma · Recurrent Craniopharyngioma · Sponsor: Sabine Mueller, MD, PhD
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
This description comes directly from the study's public registry record.
PNOC Operations Office · 877-827-3222 · PNOC029@ucsf.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Rady Children's Hospital/University of California, San Diego | San Diego, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Riley Hospital for Children at Indiana University Health | Indianapolis, Indiana, United States | Recruiting |
| John Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Dana-Farber/Boston Children's Harvard Medical School | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Children's Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| St. Louis Children's Hospital Washington University | St Louis, Missouri, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05465174